Biora Therapeutics, Inc. BIOR
Set alert
0.22 USD 0.00 0.00%
As of Mar 13, 9:30 AM ET
0.22 Day range 0.22
0.26 52-week range 19.90
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.22
- Prev close
- 0.22
- Mkt cap
- 2.04M
- Vol
- 169.45K
- Avg vol
- 132.00K
- EPS
- 0.36
- P/E
- 1.25
- Div yield
- 0.00%
More statistics
- Low
- 0.22
- High
- 0.22
- Forward P/E
- -0.04
- Beta
- 0.00
- Short ratio
- 2.37
- Inst. own
- 36.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 2.44
- 200-d avg
- 5.90
- 1y target
- 34.00
Key statistics
- Market cap
- 2.04M
- Enterprise value
- 0
- Trailing P/E
- 1.25
- Forward P/E
- -0.04
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.36
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 4.52M
- Short % of float
- 8.58%
- 50-day average
- 2.44
- 200-day average
- 5.90
Analyst view
Consensus: none
Price target (mean) 34.00 +15354.5% upside
Now 0.22
- Target (low)
- 23.00
- Target (mean)
- 34.00
- Target (high)
- 45.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate 0.00.
Financials — quick view
BIOR Revenue — quarterly 32.00K
BIOR Net income — quarterly -18.40M
BIOR EPS — quarterly -5.04
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -3.85 | -6.08 | -2.23 | -57.92% |
| Aug 12, 2024 | Jun 1, 2024 | -4.50 | — | — | — |
| Aug 12, 2024 | Jun 1, 2024 | -4.50 | -3.50 | +1.00 | +22.22% |
| May 15, 2024 | Mar 1, 2024 | -4.50 | -6.10 | -1.60 | -35.56% |
| May 15, 2024 | Mar 1, 2024 | -4.50 | — | — | — |
| Mar 26, 2024 | Dec 1, 2023 | -6.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jan 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 2, 2023 | HC Wainwright & Co. | main | Buy | Buy |
About Biora Therapeutics, Inc.
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bioratherapeutics.com
News
- Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
- Earnings Scheduled For November 14, 2024
- Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
- Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Biora Therapeutics, Inc. (BIOR) Q2 2024 Earnings Call Transcript
- Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
- Biora Therapeutics Announces Funding Agreement with Existing Investors
Your note
Sign in to keep a note on BIOR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTER JEFFREY D | Director | Stock Award(Grant) | Jun 4, 2024 | 31,546 |
| ATHYRIUM OPPORTUNITIES III CO-INVEST 1 L.P. | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Sep 17, 2023 | 0 |
| D'ESPARBES ERIC | Chief Financial Officer | Stock Award(Grant) | Feb 14, 2024 | 603,662 |
| HOWE JILL ANN | Director | Stock Award(Grant) | Jun 4, 2024 | 31,916 |
| KOTZIN BRIAN L | Director | Stock Award(Grant) | Jun 4, 2024 | 30,746 |
| MOHANTY ADITYA P | Chief Executive Officer | Stock Award(Grant) | Feb 14, 2024 | 1,539,490 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Athyrium Capital Management, LP | 24.17% | 1,092,976 | 491.84K | Sep 29, 2024 |
| Vanguard Group Inc | 1.54% | 69,733 | 31.38K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.35% | 15,630 | 7.03K | Sep 29, 2024 |
| Morgan Stanley | 0.32% | 14,503 | 6.53K | Sep 29, 2024 |
| Northern Trust Corporation | 0.15% | 6,857 | 3.08K | Sep 29, 2024 |
| Blackrock Inc. | 0.14% | 6,161 | 2.77K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.82% | 37,203 | 16.74K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.72% | 32,530 | 14.64K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.18% | 8,291 | 3.73K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 3,487 | 1.57K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.04% | 1,724 | 775 | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.03% | 1,408 | 633 | Oct 30, 2024 |